748 related articles for article (PubMed ID: 34341578)
21. Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma.
Chong WQ; Lim CM; Sinha AK; Tan CS; Chan GHJ; Huang Y; Kumarakulasinghe NB; Sundar R; Jeyasekharan AD; Loh WS; Tay JK; Yadav K; Wang L; Wong AL; Kong LR; Soo RA; Lau JA; Soon YY; Goh RM; Ho FCH; Chong SM; Lee SC; Loh KS; Tai BC; Lim YC; Goh BC
Clin Cancer Res; 2020 Oct; 26(20):5320-5328. PubMed ID: 32816944
[TBL] [Abstract][Full Text] [Related]
22. A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11).
Jung HA; Park KU; Cho S; Lim J; Lee KW; Hong MH; Yun T; An HJ; Park WY; Pereira S; Ock CY; Keam B
Clin Cancer Res; 2022 Oct; 28(19):4240-4247. PubMed ID: 35819451
[TBL] [Abstract][Full Text] [Related]
23. Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial.
Lu S; Zhang W; Wu L; Wang W; Zhang P; ; Fang W; Xing W; Chen Q; Yang L; Mei J; Tan L; Sun X; Xu S; Hu X; Yu G; Yu D; Yang N; Chen Y; Shan J; Xing L; Tian H; Zhang X; Zhou M; Fang H; Wu G; Liu Y; Ye M; Cao L; Jiang J; Li X; Zhu L; Li D; Kang M; Zhong A; Chen K; Wu N; Sun Q; Ma H; Cai K; Wang C; Lin G; Zhu K; Zhang Y; Zhang X; Hu H; Zhang W; Chen J; Yang Z; Hang X; Hu J; Huang Y; Zhang Z; Zhang L; Zhang L; Liu L; Lin D; Zhang J; Chen G; Li Y; Zhu L; Wang W; Yu W; Cao D; Keegan P; Yao S
JAMA; 2024 Jan; 331(3):201-211. PubMed ID: 38227033
[TBL] [Abstract][Full Text] [Related]
24. Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.
Yan XQ; Ye MJ; Zou Q; Chen P; He ZS; Wu B; He DL; He CH; Xue XY; Ji ZG; Chen H; Zhang S; Liu YP; Zhang XD; Fu C; Xu DF; Qiu MX; Lv JJ; Huang J; Ren XB; Cheng Y; Qin WJ; Zhang X; Zhou FJ; Ma LL; Guo JM; Ding DG; Wei SZ; He Y; Guo HQ; Shi BK; Liu L; Liu F; Hu ZQ; Jin XM; Yang L; Zhu SX; Liu JH; Huang YH; Xu T; Liu B; Sun T; Wang ZJ; Jiang HW; Yu DX; Zhou AP; Jiang J; Luan GD; Jin CL; Xu J; Hu JX; Huang YR; Guo J; Zhai W; Sheng XN
Ann Oncol; 2024 Feb; 35(2):190-199. PubMed ID: 37872020
[TBL] [Abstract][Full Text] [Related]
25. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432.
Wang F; Wei XL; Wang FH; Xu N; Shen L; Dai GH; Yuan XL; Chen Y; Yang SJ; Shi JH; Hu XC; Lin XY; Zhang QY; Feng JF; Ba Y; Liu YP; Li W; Shu YQ; Jiang Y; Li Q; Wang JW; Wu H; Feng H; Yao S; Xu RH
Ann Oncol; 2019 Sep; 30(9):1479-1486. PubMed ID: 31236579
[TBL] [Abstract][Full Text] [Related]
26. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
27. First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial.
Song Y; Zhang B; Xin D; Kou X; Tan Z; Zhang S; Sun M; Zhou J; Fan M; Zhang M; Song Y; Li S; Yuan Y; Zhuang W; Zhang J; Zhang L; Jiang H; Gu K; Ye H; Ke Y; Li J; Wang Q; Zhu J; Huang J;
Nat Med; 2023 Feb; 29(2):473-482. PubMed ID: 36732627
[TBL] [Abstract][Full Text] [Related]
28. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
[TBL] [Abstract][Full Text] [Related]
29. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma.
Zhang Y; Chen L; Hu GQ; Zhang N; Zhu XD; Yang KY; Jin F; Shi M; Chen YP; Hu WH; Cheng ZB; Wang SY; Tian Y; Wang XC; Sun Y; Li JG; Li WF; Li YH; Tang LL; Mao YP; Zhou GQ; Sun R; Liu X; Guo R; Long GX; Liang SQ; Li L; Huang J; Long JH; Zang J; Liu QD; Zou L; Su QF; Zheng BM; Xiao Y; Guo Y; Han F; Mo HY; Lv JW; Du XJ; Xu C; Liu N; Li YQ; Chua MLK; Xie FY; Sun Y; Ma J
N Engl J Med; 2019 Sep; 381(12):1124-1135. PubMed ID: 31150573
[TBL] [Abstract][Full Text] [Related]
30. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
Winer EP; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Zhou X; Karantza V; Mejia J; Cortes J;
Lancet Oncol; 2021 Apr; 22(4):499-511. PubMed ID: 33676601
[TBL] [Abstract][Full Text] [Related]
31. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Sezer A; Kilickap S; Gümüş M; Bondarenko I; Özgüroğlu M; Gogishvili M; Turk HM; Cicin I; Bentsion D; Gladkov O; Clingan P; Sriuranpong V; Rizvi N; Gao B; Li S; Lee S; McGuire K; Chen CI; Makharadze T; Paydas S; Nechaeva M; Seebach F; Weinreich DM; Yancopoulos GD; Gullo G; Lowy I; Rietschel P
Lancet; 2021 Feb; 397(10274):592-604. PubMed ID: 33581821
[TBL] [Abstract][Full Text] [Related]
32. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Vandormael K; Riccio A; Yang J; Pietanza MC; Brahmer JR
J Clin Oncol; 2019 Mar; 37(7):537-546. PubMed ID: 30620668
[TBL] [Abstract][Full Text] [Related]
33. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
Powles T; Park SH; Voog E; Caserta C; Valderrama BP; Gurney H; Kalofonos H; Radulović S; Demey W; Ullén A; Loriot Y; Sridhar SS; Tsuchiya N; Kopyltsov E; Sternberg CN; Bellmunt J; Aragon-Ching JB; Petrylak DP; Laliberte R; Wang J; Huang B; Davis C; Fowst C; Costa N; Blake-Haskins JA; di Pietro A; Grivas P
N Engl J Med; 2020 Sep; 383(13):1218-1230. PubMed ID: 32945632
[TBL] [Abstract][Full Text] [Related]
34. Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12).
Zhou C; Wu L; Fan Y; Wang Z; Liu L; Chen G; Zhang L; Huang D; Cang S; Yang Z; Zhou J; Zhou C; Li B; Li J; Fan M; Cui J; Li Y; Zhao H; Fang J; Xue J; Hu C; Sun P; Du Y; Zhou H; Wang S; Zhang W
J Thorac Oncol; 2021 Sep; 16(9):1501-1511. PubMed ID: 34048947
[TBL] [Abstract][Full Text] [Related]
35. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
Kindler HL; Karrison TG; Gandara DR; Lu C; Krug LM; Stevenson JP; Jänne PA; Quinn DI; Koczywas MN; Brahmer JR; Albain KS; Taber DA; Armato SG; Vogelzang NJ; Chen HX; Stadler WM; Vokes EE
J Clin Oncol; 2012 Jul; 30(20):2509-15. PubMed ID: 22665541
[TBL] [Abstract][Full Text] [Related]
36. Clinical trial data of Anti-PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: A review.
Adkins DR; Haddad RI
Cancer Treat Rev; 2022 Sep; 109():102428. PubMed ID: 35753157
[TBL] [Abstract][Full Text] [Related]
37. Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
Chen C; Zhou Y; Zhang X; Fu S; Lin Z; Fang W; Yang Y; Huang Y; Zhao H; Hong S; Zhang L
Cancer Med; 2020 Mar; 9(5):1721-1732. PubMed ID: 31955525
[TBL] [Abstract][Full Text] [Related]
38. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.
Pinto C; Zucali PA; Pagano M; Grosso F; Pasello G; Garassino MC; Tiseo M; Soto Parra H; Grossi F; Cappuzzo F; de Marinis F; Pedrazzoli P; Bonomi M; Gianoncelli L; Perrino M; Santoro A; Zanelli F; Bonelli C; Maconi A; Frega S; Gervasi E; Boni L; Ceresoli GL
Lancet Oncol; 2021 Oct; 22(10):1438-1447. PubMed ID: 34499874
[TBL] [Abstract][Full Text] [Related]
39. Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial.
Zhao C; Miao J; Shen G; Li J; Shi M; Zhang N; Hu G; Chen X; Hu X; Wu S; Chen J; Shao X; Wang L; Han F; Mai H; Chua MLK; Xie C
Ann Oncol; 2019 Apr; 30(4):637-643. PubMed ID: 30689735
[TBL] [Abstract][Full Text] [Related]
40. Immune checkpoint inhibition in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A CAPTAIN-1st and JUPITER-02 trial-based cost-effectiveness analysis.
Tian K; Han J; Wang Z; Chen J
Oral Oncol; 2022 May; 128():105842. PubMed ID: 35428025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
